CRISPR-Cas9 is a revolutionary genome editing technique that allows for precise DNA cleavage and editing by guiding the Cas9 nuclease to specific DNA sequences using a guide RNA (gRNA). The CRISPR-Cas9 system is derived from a bacterial immune system that uses RNA-guided nucleases to cleave and degrade foreign DNA, such as viral DNA. In recent years, the CRISPR-Cas9 system has been adapted for use in many areas of biological research, including gene therapy, drug discovery, and agricultural biotechnology.
CRISPR/Cas9-based protein degradation is a genome editing technique that has been adapted for targeted protein degradation. The CRISPR/Cas9 system is a powerful tool that allows for precise DNA cleavage and editing by guiding the Cas9 nuclease to specific DNA sequences using a guide RNA (gRNA). In CRISPR/Cas9-based protein degradation, the Cas9 nuclease is fused to a domain that recruits the ubiquitin-proteasome system, resulting in the degradation of the target protein. CRISPR/Cas9-based protein degradation has many potential applications in drug discovery and development. It can be used to selectively degrade disease-causing proteins, such as mutant or overexpressed proteins, which are often difficult to target using traditional small-molecule inhibitors. However, the success of CRISPR/Cas9-based protein degradation depends on efficient and specific delivery of the gRNA and Cas9-fusion protein to the target cells or tissues.
ALL Chemistry Inc. provides CRISPR/Cas9-based protein degradation services which include:
Design and synthesis of gRNA and Cas9 fusion protein: The first step is to design and synthesize a gRNA that targets the gene encoding the target protein. The Cas9 nuclease is then fused to a domain that recruits the ubiquitin-proteasome system, such as the F-box domain of the E3 ubiquitin ligase, to create a Cas9-fusion protein.
Delivery of gRNA and Cas9-fusion protein: The next step is to deliver the gRNA and Cas9-fusion protein to the target cells or tissues. This can be done through various methods, such as transfection or viral vectors.
Binding of the gRNA and Cas9-fusion protein to the target gene: The gRNA guides the Cas9-fusion protein to the target gene, where it binds and cleaves the DNA.
Recruitment of the ubiquitin-proteasome system: The Cas9-fusion protein recruits the ubiquitin-proteasome system to the site of DNA cleavage, resulting in the degradation of the target protein.
Monitoring protein degradation: The effectiveness of CRISPR/Cas9-based protein degradation can be monitored by measuring the reduction in protein expression levels using various techniques, such as western blotting and immunofluorescence.
+1 609 531 0668
STE 104 Marlton , NJ 08053, USA